Tactile Systems (TCMD) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 5% year-over-year to $73.1 million, with lymphedema up 4–4.4% and airway clearance up 10%.

• Net income was $5.2 million, down from $22.3 million in Q3 2023 due to prior-year tax benefits and earn-out adjustments.

• Gross margin expanded by 410 basis points year-over-year to 75.0%, driven by lower material and warranty costs.

• Adjusted EBITDA increased to $10.7 million (14.6% of sales), marking the 10th consecutive quarter of improvement.

• Cash and cash equivalents rose to $82.1 million as of September 30, 2024, with $27 million in outstanding borrowings.

Financial highlights

• Q3 2024 revenue: $73.1 million (+5% YoY); nine months: $207.4 million (+5% YoY).

• Lymphedema revenue: $65.3 million (+4% YoY); airway clearance: $7.8 million (+10% YoY).

• GAAP gross margin: 75% (vs. 70.9% prior year); non-GAAP gross margin: 75.4% (vs. 71.4%).

• Operating income: $6.8 million (down from $8.0 million YoY); non-GAAP operating income: $7.9 million (up from $5.2 million).

• Operating cash flow for nine months: $24.3 million (up from $17.5 million YoY).

Outlook and guidance

• 2024 revenue guidance revised to $292–$295 million (6–8% growth), down from $293–$298 million.

• Adjusted EBITDA guidance raised to $35–$37 million (previously $34–$36 million).

• GAAP gross margin expected at ~74% for 2024.

• Management expects liquidity and cash flow to be sufficient for at least the next twelve months.